Journal of Molecular Neuroscience

, Volume 60, Issue 1, pp 46–62 | Cite as

Neuroinflammation-Induced Memory Deficits Are Amenable to Treatment with d-Cycloserine

  • Sigal Liraz-Zaltsman
  • Rami Yaka
  • Dalia Shabashov
  • Esther Shohami
  • Anat Biegon


Cognitive deficits, especially memory loss, are common following many types of brain insults which are associated with neuroinflammation, although the underlying mechanisms are not entirely clear. The present study aimed to characterize the long-term cognitive and behavioral impairments in a mouse model of neuroinflammation in the absence of other insults and to evaluate the therapeutic potential of d-cycloserine (DCS). DCS is a co-agonist of the NMDA receptor that ameliorates cognitive deficits in models of TBI and stroke. Using a mouse model of global neuroinflammation induced by intracisternal (i.c.) administration of endotoxin (LPS), we found long-lasting microgliosis, memory deficits, impaired LTP, and reduced levels of the obligatory NR1 subunit of the NMDA receptor. A single administration of DCS, 1 day after i.c. LPS reduced microgliosis, reversed the cognitive deficits and restored LTP and NR1 levels. These results demonstrate that neuroinflammation alone, in the absence of trauma or ischemia, can cause persistent (>6 months) memory deficits linked to deranged NNMDA receptor function and suggest a possible role for NMDA co-agonists in reducing the cognitive sequelae of neuroinflammation.


Cognitive deficits NMDA receptors Endotoxin LPS DCS Neuroinflammation 


  1. Adeleye A, Shohami E, Nachman D, Alexandrovich A, Trembovler V, Yaka R, Shoshan Y, Dhawan J, Biegon A (2010) D-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. Eur J Pharmacol 629(1–3):25–30CrossRefPubMedGoogle Scholar
  2. Andersen JM, Lindberg V, Myhrer T (2002) Effects of scopolamine and D-cycloserine on non-spatial reference memory in rats. Behav Brain Res 129(1–2):211–216CrossRefPubMedGoogle Scholar
  3. Anderson V, Bond L, Catroppa C, Grimwood K, Keir E, Nolan T (1997) Childhood bacterial meningitis: impact of age at illness and acute medical complications on long term outcome. J Int Neuropsychol Soc 3(2):147–158PubMedGoogle Scholar
  4. Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon JS, Hoffer BJ, Greig NH, Pick CG (2011) Tumor necrosis factor-alpha synthesis inhibitor, 3,6′-dithiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. J Neurochem 118(6):1032–1042CrossRefPubMedPubMedCentralGoogle Scholar
  5. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E (2001) A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J Pharmacol Exp Ther 296(1):57–63PubMedGoogle Scholar
  6. Biegon A, Alvarado M, Budinger TF, Grossman R, Hensley K, West MS, Kotake Y, Ono M, Floyd RA (2002) Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J Neurochem 82(4):924–934CrossRefPubMedGoogle Scholar
  7. Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami E (2004) Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci U S A 101(14):5117–5122CrossRefPubMedPubMedCentralGoogle Scholar
  8. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361(6407):31–39CrossRefPubMedGoogle Scholar
  9. Boje KM (1995) Cerebrovascular permeability changes during experimental meningitis in the rat. J Pharmacol Exp Ther 274(3):1199–1203PubMedGoogle Scholar
  10. Carter JA, Neville BG, Newton CR (2003) Neuro-cognitive impairment following acquired central nervous system infections in childhood: a systematic review. Brain Res Brain Res Rev 43(1):57–69CrossRefPubMedGoogle Scholar
  11. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10(1):63–74CrossRefPubMedPubMedCentralGoogle Scholar
  12. de Araujo Furtado M, Rossetti F, Chanda S, Yourick D (2012) Exposure to nerve agents: from status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy. NeurotoxicologyGoogle Scholar
  13. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H (1992) A two-trial memory task with automated recording: study in young and aged rats. Brain Res 588(1):132–139CrossRefPubMedGoogle Scholar
  14. Dhawan J, Benveniste H, Luo Z, Nawrocky M, Smith SD, Biegon A (2011) A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke. Future Neurol 6(6):823–834CrossRefPubMedPubMedCentralGoogle Scholar
  15. Dhawan J, Benveniste H, Nawrocky M, Smith SD, Biegon A (2010) Transient focal ischemia results in persistent and widespread neuroinflammation and loss of glutamate NMDA receptors. Neuroimage 51(2):599–605CrossRefPubMedPubMedCentralGoogle Scholar
  16. Donzis EJ, Thompson LT (2014) D-cycloserine enhances both intrinsic excitability of CA1 hippocampal neurons and expression of activity-regulated cytoskeletal (Arc) protein. Neurosci Lett 571:50–54CrossRefPubMedGoogle Scholar
  17. Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP (2004) Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71(2–3):239–248CrossRefPubMedGoogle Scholar
  18. Edison P, Archer HA, Gerhard A, Hinz R, Pavese N, Turkheimer FE, Hammers A, Tai YF, Fox N, Kennedy A, Rossor M, Brooks DJ (2008) Microglia, amyloid, and cognition in Alzheimer’s disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 32(3):412–419CrossRefPubMedGoogle Scholar
  19. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data. Behav Brain Res 31(1):47–59CrossRefPubMedGoogle Scholar
  20. Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K (2014) Dementia risk after traumatic brain injury vs nonbrain trauma: the role of age and severity. JAMA Neurol 71(12):1490–1497CrossRefPubMedPubMedCentralGoogle Scholar
  21. Grossman R, Paden CM, Fry PA, Rhodes RS, Biegon A (2012) Persistent region-dependent neuroinflammation, NMDA receptor loss and atrophy in an animal model of penetrating brain injury. Future Neurol 7(3):329–339CrossRefPubMedPubMedCentralGoogle Scholar
  22. Grossman R, Shohami E, Alexandrovich A, Yatsiv I, Kloog Y, Biegon A (2003) Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study. Neuroimage 20(4):1971–1981CrossRefPubMedGoogle Scholar
  23. Guilarte TR, Kuhlmann AC, O’Callaghan JP, Miceli RC (1995) Enhanced expression of peripheral benzodiazepine receptors in trimethyltin-exposed rat brain: a biomarker of neurotoxicity. Neurotoxicology 16(3):441–450PubMedGoogle Scholar
  24. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263(5):367–377CrossRefPubMedGoogle Scholar
  25. Hauss-Wegrzyniak B, Vannucchi MG, Wenk GL (2000) Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. Brain Res 859(1):157–166CrossRefPubMedGoogle Scholar
  26. Heifets LB (1994) Antimycobacterial drugs. Semin Respir Infect 9(2):84–103PubMedGoogle Scholar
  27. Henry GK, Gross HS, Herndon CA, Furst CJ (2000) Nonimpact brain injury: neuropsychological and behavioral correlates with consideration of physiological findings. Appl Neuropsychol 7(2):65–75CrossRefPubMedGoogle Scholar
  28. Hirshler YK, Polat U, Biegon A (2010) Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats. Exp Neurol 222(1):42–50CrossRefPubMedGoogle Scholar
  29. Ho YJ, Ho SC, Pawlak CR, Yeh KY (2011) Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson’s disease dementia. Behav Brain Res 219(2):280–290CrossRefPubMedGoogle Scholar
  30. Hofmann SG, Otto MW, Pollack MH, Smits JA (2015) D-Cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update. Curr Psychiatry Rep 17(1):532CrossRefPubMedGoogle Scholar
  31. Hoogman M, van de Beek D, Weisfelt M, de Gans J, Schmand B (2007) Cognitive outcome in adults after bacterial meningitis. J Neurol Neurosurg Psychiatry 78(10):1092–1096CrossRefPubMedPubMedCentralGoogle Scholar
  32. Hovens IB, Schoemaker RG, van der Zee EA, Heineman E, Izaks GJ, van Leeuwen BL (2012) Thinking through postoperative cognitive dysfunction: how to bridge the gap between clinical and pre-clinical perspectives. Brain Behav Immun 26(7):1169–1179CrossRefPubMedGoogle Scholar
  33. Kelly DL, Sullivan KM, McEvoy JP, Mcmahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 35(4):374–381PubMedPubMedCentralGoogle Scholar
  34. Kravitz E, Gaisler-Salomon I, Biegon A (2013) Hippocampal glutamate NMDA receptor loss tracks progression in Alzheimer’s disease: quantitative autoradiography in postmortem human brain. PLoS One 8(11):e81244CrossRefPubMedPubMedCentralGoogle Scholar
  35. Laake K, Oeksengaard AR (2002) D-cycloserine for Alzheimer’s disease. Cochrane Database Syst Rev 2:CD003153PubMedGoogle Scholar
  36. Lampl Y, Boaz M, Gilad R, Lorberboym M, Dabby R, Rapoport A, Anca-Hershkowitz M, Sadeh M (2007) Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69(14):1404–1410CrossRefPubMedGoogle Scholar
  37. Lelong V, Dauphin F, Boulouard M (2001) RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology 41(4):517–522CrossRefPubMedGoogle Scholar
  38. Levite M (2014) “Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren’s syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor’s expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.”. J Neural Transm 121(8):1029–1075CrossRefPubMedGoogle Scholar
  39. Li F, Tsien JZ (2009) Memory and the NMDA receptors. N Engl J Med 361(3):302–303CrossRefPubMedPubMedCentralGoogle Scholar
  40. Lozano D, Gonzales-Portillo GS, Acosta S, de la Pena I, Tajiri N, Kaneko Y, Borlongan CV (2015) Neuroinflammatory responses to traumatic brain injury: etiology, clinical consequences, and therapeutic opportunities. Neuropsychiatr Dis Treat 11:97–106PubMedPubMedCentralGoogle Scholar
  41. Malenka RC, Nicoll RA (1999) Long-term potentiation—a decade of progress? Science 285(5435):1870–1874CrossRefPubMedGoogle Scholar
  42. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL (2004) Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 279(31):32869–32881CrossRefPubMedGoogle Scholar
  43. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA (2009) Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68(7):709–735CrossRefPubMedPubMedCentralGoogle Scholar
  44. McKee AC, Stein TD, Kiernan PT, Alvarez VE (2015) The neuropathology of chronic traumatic encephalopathy. Brain Pathol 25(3):350–364CrossRefPubMedPubMedCentralGoogle Scholar
  45. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11(1):47–60CrossRefPubMedGoogle Scholar
  46. Morris RG, Anderson E, Lynch GS, Baudry M (1986) Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319(6056):774–776CrossRefPubMedGoogle Scholar
  47. Muller N, Weidinger E, Leitner B, Schwarz MJ (2015) The role of inflammation in schizophrenia. Front Neurosci 9:372CrossRefPubMedPubMedCentralGoogle Scholar
  48. Noble F, Rubira E, Boulanouar M, Palmier B, Plotkine M, Warnet JM, Marchand-Leroux C, Massicot F (2007) Acute systemic inflammation induces central mitochondrial damage and mnesic deficit in adult Swiss mice. Neurosci Lett 424(2):106–110CrossRefPubMedGoogle Scholar
  49. Onur OA, Schlaepfer TE, Kukolja J, Bauer A, Jeung H, Patin A, Otte DM, Shah NJ, Maier W, Kendrick KM, Fink GR, Hurlemann R (2010) The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans. Biol Psychiatry 67(12):1205–1211CrossRefPubMedGoogle Scholar
  50. Papadakis M, Hawkins LM, Stephenson FA (2004) Appropriate NR1-NR1 disulfide-linked homodimer formation is requisite for efficient expression of functional, cell surface N-methyl-D-aspartate NR1/NR2 receptors. J Biol Chem 279(15):14703–14712CrossRefPubMedGoogle Scholar
  51. Pawlak CR, Chen FS, Wu FY, Ho YJ (2012) Potential of D-cycloserine in the treatment of behavioral and neuroinflammatory disorders in Parkinson’s disease and studies that need to be performed before clinical trials. Kaohsiung J Med Sci 28(8):407–417CrossRefPubMedGoogle Scholar
  52. Pozniak PD, White MK, Khalili K (2014) TNF-alpha/NF-kappaB signaling in the CNS: possible connection to EPHB2. J Neuroimmune Pharmacol 9(2):133–141CrossRefPubMedGoogle Scholar
  53. Qiu W, Zheng X, Wei Y, Zhou X, Zhang K, Wang S, Cheng L, Li Y, Ren B, Xu X, Li Y, Li M (2015) D-Alanine metabolism is essential for growth and biofilm formation of Streptococcus mutans. Microbiol, Mol OralGoogle Scholar
  54. Raghavendra Rao VL, Dogan A, Bowen KK, Dempsey RJ (2000) Traumatic brain injury leads to increased expression of peripheral-type benzodiazepine receptors, neuronal death, and activation of astrocytes and microglia in rat thalamus. Exp Neurol 161(1):102–114CrossRefPubMedGoogle Scholar
  55. Rao AA, Ye H, Decker PA, Howe CL, Wetmore C (2011) Therapeutic doses of cranial irradiation induce hippocampus-dependent cognitive deficits in young mice. J Neurooncol 105(2):191–198CrossRefPubMedGoogle Scholar
  56. Rathbone AT, Tharmaradinam S, Jiang S, Rathbone MP, Kumbhare DA (2015) A review of the neuro- and systemic inflammatory responses in post concussion symptoms: introduction of the “post-inflammatory brain syndrome” PIBS. Brain Behav Immun 46:1–16CrossRefPubMedGoogle Scholar
  57. Riedel G, Platt B, Micheau J (2003) Glutamate receptor function in learning and memory. Behav Brain Res 140(1–2):1–47CrossRefPubMedGoogle Scholar
  58. Rodriguez JI, Kern JK (2011) Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biol 7(2–4):205–213CrossRefPubMedPubMedCentralGoogle Scholar
  59. Rouaud E, Billard JM (2003) D-cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slices. Br J Pharmacol 140(6):1051–1056CrossRefPubMedPubMedCentralGoogle Scholar
  60. Sauvage MM, Nakamura NH, Beer Z (2013) Mapping memory function in the medial temporal lobe with the immediate-early gene Arc. Behav Brain Res 254:22–33CrossRefPubMedGoogle Scholar
  61. Schneider JS, Tinker JP, Van Velson M, Giardiniere M (2000) Effects of the partial glycine agonist D-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 860(1–2):190–194CrossRefPubMedGoogle Scholar
  62. Scoccianti S, Detti B, Cipressi S, Iannalfi A, Franzese C, Biti G (2012) Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol 108(2):291–308CrossRefPubMedGoogle Scholar
  63. Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T, Heneka MT (2007) Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol 204(2):733–740CrossRefPubMedGoogle Scholar
  64. Sheppard E, Lippe S (2012) Cognitive outcome of status epilepticus in children. Epilepsy Res Treat 2012:984124PubMedPubMedCentralGoogle Scholar
  65. Shih RH, Wang CY, Yang CM (2015) NF-kappaB signaling pathways in neurological inflammation: a mini review. Front Mol Neurosci 8:77CrossRefPubMedPubMedCentralGoogle Scholar
  66. Shohami E, Biegon A (2014) Novel approach to the role of NMDA receptors in traumatic brain injury. CNS Neurol Disord Drug Targets 13(4):567–573CrossRefPubMedGoogle Scholar
  67. Simiand J, Keane PE, Morre M (1984) The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology (Berl) 84(1):48–53CrossRefGoogle Scholar
  68. Sparkman NL, Kohman RA, Garcia AK, Boehm GW (2005a) Peripheral lipopolysaccharide administration impairs two-way active avoidance conditioning in C57BL/6J mice. Physiol Behav 85(3):278–288CrossRefPubMedGoogle Scholar
  69. Sparkman NL, Kohman RA, Scott VJ, Boehm GW (2005b) Bacterial endotoxin-induced behavioral alterations in two variations of the Morris water maze. Physiol Behav 86(1–2):244–251CrossRefPubMedGoogle Scholar
  70. Stein TD, Alvarez VE, McKee AC (2014) Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther 6(1):4CrossRefPubMedPubMedCentralGoogle Scholar
  71. Stein TD, Montenigro PH, Alvarez VE, Xia W, Crary JF, Tripodis Y, Daneshvar DH, Mez J, Solomon T, Meng G, Kubilus CA, Cormier KA, Meng S, Babcock K, Kiernan P, Murphy L, Nowinski CJ, Martin B, Dixon D, Stern RA, Cantu RC, Kowall NW, McKee AC (2015) Beta-amyloid deposition in chronic traumatic encephalopathy. Neuropathol, ActaGoogle Scholar
  72. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA (1996) NMDA receptors: from genes to channels. Trends Pharmacol Sci 17(10):348–355CrossRefPubMedGoogle Scholar
  73. Sun L, Margolis FL, Shipley MT, Lidow MS (1998) Identification of a long variant of mRNA encoding the NR3 subunit of the NMDA receptor: its regional distribution and developmental expression in the rat brain. FEBS Lett 441(3):392–396CrossRefPubMedGoogle Scholar
  74. Temple MD, Hamm RJ (1996) Chronic, post-injury administration of D-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res 741(1–2):246–251CrossRefPubMedGoogle Scholar
  75. Thiel A, Cechetto DF, Heiss WD, Hachinski V, Whitehead SN (2014) Amyloid burden, neuroinflammation, and links to cognitive decline after ischemic stroke. Stroke 45(9):2825–2829CrossRefPubMedGoogle Scholar
  76. Tsenter J, Beni-Adani L, Assaf Y, Alexandrovich AG, Trembovler V, Shohami E (2008) Dynamic changes in the recovery after traumatic brain injury in mice: effect of injury severity on T2-weighted MRI abnormalities, and motor and cognitive functions. J Neurotrauma 25(4):324–333CrossRefPubMedGoogle Scholar
  77. Tyler AL, Mahoney JM, Richard GR, Holmes GL, Lenck-Santini PP, Scott RC (2012) Functional network changes in hippocampal CA1 after status epilepticus predict spatial memory deficits in rats. J Neurosci 32(33):11365–11376CrossRefPubMedPubMedCentralGoogle Scholar
  78. Vogt MA, Mallien AS, Pfeiffer N, Inta I, Gass P, Inta D (2015) Minocycline does not evoke anxiolytic and antidepressant-like effects in C57BL/6 mice. Behav Brain Res 301:96–101CrossRefPubMedGoogle Scholar
  79. Walsh RN, Cummins RA (1976) The Open-Field Test: a critical review. Psychol Bull 83(3):482–504CrossRefPubMedGoogle Scholar
  80. Webster SJ, Van Eldik LJ, Watterson DM, Bachstetter AD (2015) Closed head injury in an age-related Alzheimer mouse model leads to an altered neuroinflammatory response and persistent cognitive impairment. J Neurosci 35(16):6554–6569CrossRefPubMedPubMedCentralGoogle Scholar
  81. Yaka R, Biegon A, Grigoriadis N, Simeonidou C, Grigoriadis S, Alexandrovich AG, Matzner H, Schumann J, Trembovler V, Tsenter J, Shohami E (2007) D-Cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. Faseb J 21(9):2033–2041CrossRefPubMedGoogle Scholar
  82. Zerche M, Weissenborn K, Ott C, Dere E, Asif AR, Worthmann H, Hassouna I, Rentzsch K, Tryc AB, Dahm L, Steiner J, Binder L, Wiltfang J, Siren AL, Stocker W, Ehrenreich H (2015) Preexisting serum autoantibodies against the NMDAR subunit NR1 modulate evolution of lesion size in acute ischemic stroke. Stroke 46(5):1180–1186CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Sigal Liraz-Zaltsman
    • 1
    • 2
  • Rami Yaka
    • 2
  • Dalia Shabashov
    • 2
  • Esther Shohami
    • 2
  • Anat Biegon
    • 1
    • 3
  1. 1.The Joseph Sagol Neuroscience CenterSheba Medical CenterRamat GanIsrael
  2. 2.Department of Pharmacology, School of PharmacyHebrew UniversityJerusalemIsrael
  3. 3.Department of NeurologyStony Brook University School of MedicineStony BrookUSA

Personalised recommendations